Compare Bilibili Inc (BILI) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bilibili Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Bilibili Inc trades at $17.6 (market cap $7.65B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $360.38 (market cap $9.43B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| BILI | BIO | |
|---|---|---|
Market Cap | $7.65B | $9.43B |
Sector | Media | Health |
52-Week High | $35.92 | $356.25 |
52-Week Low | $15.96 | $241.71 |
Enterprise Value | $5.49B | $9.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bilibili (BILI) trades at $17.46, down 8.06% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q1 2026 EPS of $0.19 exceeding expectations. Revenue growth remains steady at 7% year-over-year, with improving margins and a $300 million share repurchase program supporting shareholder value. Analyst sentiment remains overwhelmingly positive with 83% buy ratings.
The investment case balances strong fundamentals against technical weakness. Upside drivers include advertising growth, AI integration, and margin expansion, while risks involve competitive pressures and China's economic environment. With attractive valuation metrics and institutional support, BILI presents a compelling opportunity for patient investors despite near-term volatility.
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
